CorMedix Completes Phase III Enrollment for REZZAYO Antifungal Prophylaxis in Bone Marrow Transplant Patients
- CorMedix announced completion of enrollment in the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for preventing fungal infections in adult patients undergoing allogeneic blood and marrow transplantation.
- The study compares once-weekly rezafungin dosing versus standard antimicrobial regimens, with the primary endpoint of fungal-free survival at day 90 and topline results expected in Q2 2026.
- REZZAYO represents a significant market opportunity with an estimated 130,000 patients constituting the addressable market for antifungal prophylaxis in the U.S. and a total addressable market exceeding $2 billion.
- The drug currently has orphan drug exclusivity through 2035 and patent coverage through 2038, positioning CorMedix for potential FDA approval in this high-risk patient population with critical unmet medical needs.